Logo image of VYNE

VYNE THERAPEUTICS INC (VYNE) Stock Fundamental Analysis

NASDAQ:VYNE - Nasdaq - US92941V3087 - Common Stock - Currency: USD

0.3788  +0.01 (+2.38%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to VYNE. VYNE was compared to 193 industry peers in the Pharmaceuticals industry. VYNE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VYNE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VYNE has reported negative net income.
VYNE had a negative operating cash flow in the past year.
VYNE had negative earnings in each of the past 5 years.
VYNE had a negative operating cash flow in each of the past 5 years.
VYNE Yearly Net Income VS EBIT VS OCF VS FCFVYNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -74.79%, VYNE is doing worse than 68.39% of the companies in the same industry.
The Return On Equity of VYNE (-95.61%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -74.79%
ROE -95.61%
ROIC N/A
ROA(3y)-48.52%
ROA(5y)-105.55%
ROE(3y)-60.82%
ROE(5y)-202.97%
ROIC(3y)N/A
ROIC(5y)N/A
VYNE Yearly ROA, ROE, ROICVYNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VYNE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VYNE Yearly Profit, Operating, Gross MarginsVYNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

6

2. Health

2.1 Basic Checks

VYNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
VYNE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for VYNE has been increased compared to 5 years ago.
VYNE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VYNE Yearly Shares OutstandingVYNE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
VYNE Yearly Total Debt VS Total AssetsVYNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

VYNE has an Altman-Z score of -19.80. This is a bad value and indicates that VYNE is not financially healthy and even has some risk of bankruptcy.
VYNE has a worse Altman-Z score (-19.80) than 80.31% of its industry peers.
VYNE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.8
ROIC/WACCN/A
WACC9.33%
VYNE Yearly LT Debt VS Equity VS FCFVYNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

VYNE has a Current Ratio of 4.47. This indicates that VYNE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.47, VYNE is in the better half of the industry, outperforming 66.32% of the companies in the same industry.
VYNE has a Quick Ratio of 4.47. This indicates that VYNE is financially healthy and has no problem in meeting its short term obligations.
VYNE has a better Quick ratio (4.47) than 67.36% of its industry peers.
Industry RankSector Rank
Current Ratio 4.47
Quick Ratio 4.47
VYNE Yearly Current Assets VS Current LiabilitesVYNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

VYNE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.83%, which is quite impressive.
The Revenue has grown by 42.69% in the past year. This is a very strong growth!
VYNE shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.63% yearly.
EPS 1Y (TTM)81.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
Revenue 1Y (TTM)42.69%
Revenue growth 3Y-18.63%
Revenue growth 5YN/A
Sales Q2Q%106.12%

3.2 Future

The Earnings Per Share is expected to grow by 46.85% on average over the next years. This is a very strong growth
VYNE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 209.11% yearly.
EPS Next Y-11.22%
EPS Next 2Y9.66%
EPS Next 3Y9.29%
EPS Next 5Y46.85%
Revenue Next Year31.25%
Revenue Next 2Y-8.14%
Revenue Next 3Y-25.99%
Revenue Next 5Y209.11%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VYNE Yearly Revenue VS EstimatesVYNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 2031 50M 100M 150M 200M 250M
VYNE Yearly EPS VS EstimatesVYNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VYNE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VYNE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VYNE Price Earnings VS Forward Price EarningsVYNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VYNE Per share dataVYNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.66%
EPS Next 3Y9.29%

More info and screens

0

5. Dividend

5.1 Amount

VYNE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VYNE THERAPEUTICS INC

NASDAQ:VYNE (8/5/2025, 12:08:06 PM)

0.3788

+0.01 (+2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-12 2025-08-12
Inst Owners46.08%
Inst Owner Change0.17%
Ins Owners2.31%
Ins Owner Change-3%
Market Cap6.31M
Analysts84
Price Target6.5 (1615.95%)
Short Float %2.24%
Short Ratio0.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.94%
Min EPS beat(2)9.5%
Max EPS beat(2)32.39%
EPS beat(4)2
Avg EPS beat(4)1.85%
Min EPS beat(4)-20.98%
Max EPS beat(4)32.39%
EPS beat(8)4
Avg EPS beat(8)-13.08%
EPS beat(12)7
Avg EPS beat(12)-3.02%
EPS beat(16)10
Avg EPS beat(16)-0.54%
Revenue beat(2)1
Avg Revenue beat(2)127.45%
Min Revenue beat(2)-41.18%
Max Revenue beat(2)296.08%
Revenue beat(4)3
Avg Revenue beat(4)84.8%
Min Revenue beat(4)-41.18%
Max Revenue beat(4)296.08%
Revenue beat(8)4
Avg Revenue beat(8)36.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)24.14%
EPS NY rev (1m)3%
EPS NY rev (3m)12.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)200%
Revenue NY rev (1m)0%
Revenue NY rev (3m)250%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.43
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 0.14
EV/EBITDA N/A
EPS(TTM)-0.99
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)-2.25
FCFYN/A
OCF(TTM)-2.25
OCFYN/A
SpS0.04
BVpS2.65
TBVpS2.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -74.79%
ROE -95.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.52%
ROA(5y)-105.55%
ROE(3y)-60.82%
ROE(5y)-202.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.47
Quick Ratio 4.47
Altman-Z -19.8
F-Score4
WACC9.33%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
EPS Next Y-11.22%
EPS Next 2Y9.66%
EPS Next 3Y9.29%
EPS Next 5Y46.85%
Revenue 1Y (TTM)42.69%
Revenue growth 3Y-18.63%
Revenue growth 5YN/A
Sales Q2Q%106.12%
Revenue Next Year31.25%
Revenue Next 2Y-8.14%
Revenue Next 3Y-25.99%
Revenue Next 5Y209.11%
EBIT growth 1Y-47.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.2%
EBIT Next 3Y-17.79%
EBIT Next 5Y-8.12%
FCF growth 1Y-46.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.06%
OCF growth 3YN/A
OCF growth 5YN/A